MGTA News and Press, Magenta Therapeutics Inc.

2023-07-31 01:50:08 ET Summary Magenta Therapeutics is exploring a potential merger due to failed developments of its former products. The deal has to be approved by shareholders in a vote, which may not approve the transaction and force the company to liquidate its assets, allowi...

2023-07-28 10:36:08 ET Summary Magenta Therapeutics, a previously promising biotech firm, halted operations following a clinical trial tragedy, but its merger with Dianthus Therapeutics provides opportunities and a potential brighter future. Dianthus Therapeutics, focused on devel...

NEW YORK, NY / ACCESSWIRE / May 14, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Midwest Holding Inc. (NASDAQ: MDWT)...

NEW YORK, NY / ACCESSWIRE / May 11, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Magenta Therapeutics, Inc. (NASD...

NEW YORK, NY / ACCESSWIRE / May 4, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Ruth's Hospitality Group, Inc. (NASD...

Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approx...

2023-03-31 17:35:12 ET Magenta Therapeutics ( NASDAQ: MGTA ) announced a stockholder rights plan for one year on Friday in an attempt to reduce the likelihood of unwanted bids for the company ownership. Per the terms, if a party secures 10% or more of beneficial ownership ...

CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the &...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock It’s time to start the final day of trading this week with a look at the biggest pre-market stock movers for Friday! Moving stocks are SEC filings, public offerings, earnings, and more. Let...

Magenta Therapeutics ( NASDAQ: MGTA ) has added 47% in post-market trading after saying it will stop development of its program and conduct a review of strategic alternatives. These alternatives can include an acquisition, merger, or business combination. Over the last yea...